Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Peter Sleight,
This was a well attended session with 4 excellent lectures.Giovanni de Simone (Napoli) stated that males & females had equal numbers of cardiac myocytes but males at puberty developed greater left ventricular hypertrophy (LVH). Concentric hypertrophy caused fibrosis. Knockout mice had preserved LV function despite no LVH. LV mass is linearly related to body size from mice to horses! The best relation for LVM was for fat free body mass, so body surface area (BSA) fails. Trials & clinic produce similar regression, although reduced by metabolic risk factors. Frank Ruschitska (Zurich) emphasised the role of heart failure (HF) for morbidity & mortality - neglected compared with stroke or MI. Data by Tocci (J Hyp 2008) showed that HF caused twice as many deaths as all cancers combined. In 60-69 year old males, congestive HF (CHF) accounted for 20% of total mortality (Yusuf & Pitt, Circulation 2002). CHF is eminently treatable, but for hypertension, this needs to be early! New regression trials will report in the next year or two. Finally, he discussed choice of diuretic, stating that the best evidence favoured Indapamide or chlorthalidone, not low dose thiazides.Tony Heagerty cited the importance of LVH in ischaemic heart disease & old versus newer drugs. The main factor was the resultant blood pressure, not the drugs used. He also discussed the J-curve, not very important for most hypertensives. New consensus favours a target below 140/90 mmHg.Finally, Gregory Lip (Birmingham, UK) showed the importance of HT for atrial fibrillation – pointing out ethnic differences, where HT is much more a factor for Afro-Carribeans than Indo/Asians.
Hypertension and the heart
© 2017 European Society of Cardiology. All rights reserved